#USA #Tampa #Concept Medical #SIRONA Trial #Sirolimus Balloon

Concept Medical Celebrates Positive SIRONA Trial Results as New Hope for PAD Therapy

Concept Medical's Positive SIRONA Trial Results

In an encouraging development for vascular health, Concept Medical Inc., renowned for its cutting-edge drug-delivery technologies, has reported promising results from its SIRONA trial. This pivotal study examines the use of a sirolimus-coated balloon, known as MagicTouch -PTA, as an alternative treatment for patients suffering from Peripheral Artery Disease (PAD). The findings were presented by lead investigator Prof. Ulf Teichgräber during the TCT USA 2024 conference, and they highlight the viability of sirolimus as an effective option alongside paclitaxel-coated balloons.

The SIRONA Trial: A Breakdown

The SIRONA trial was a randomized, multicenter study involving 482 patients across 25 sites in Germany and Austria. The objective was to compare the sirolimus-coated balloon with seven commercially available paclitaxel-coated balloons in treating femoropopliteal artery lesions. The trial aimed to establish the drug-coated balloon's efficacy and safety profile for patients suffering from PAD.

Key Findings:

- Primary Patency Rate: The study revealed a primary patency rate of 73.8% for the MagicTouch PTA, compared to 75% for the paclitaxel drug-coated balloons (DCBs). While this indicates a slight difference of 1.2 percentage points, it met the predefined non-inferiority endpoint for primary patency.
- Safety Profile: At 12 months post-procedure, both treatment groups exhibited comparable results for clinically driven target lesion revascularization (cdTLR), with rates of 92.9% in the MagicTouch PTA group and 95.4% in the paclitaxel group, indicating no significant safety differences.
- Functional Improvements: Functional data showed similar enhancements between the sirolimus and paclitaxel groups, with an impressive 89% of patients experiencing improvements of one or more Rutherford stages.

Implications of the Findings

Prof. Teichgräber emphasized the historical reliance on paclitaxel-coated balloons for PAD treatment, particularly in femoropopliteal segments. However, concerns surrounding safety have prompted the exploration of sirolimus as a pharmaceutical alternative. The SIRONA trial results endorse sirolimus's efficacy, paving the way for more personalized approaches in treating PAD.

Prof. Dierk Scheinert, another proponent of the trial, lauded the randomization approach in the study and noted that it provides significant evidence supporting sirolimus-coated balloons for a broader range of femoropopliteal obstructions.

Commitment to Innovation

Dr. Manish Doshi, founder, and CEO of Concept Medical, remarked that the results from the SIRONA trial underscore the company's commitment to innovation in vascular therapy. The study aligns with their mission to develop evidence-based, patient-centered solutions aimed at improving outcomes for PAD patients.

About Concept Medical

Founded in Tampa, Florida, Concept Medical is a global leader in drug-delivery platforms, with the MagicTouch sirolimus-coated balloon revolutionizing both coronary and peripheral intervention landscapes. Their ongoing dedication to rigorous clinical research, demonstrated through the SIRONA trial, positions them at the forefront of developing the next generation of vascular therapies.